Biotechnology

Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting

SUZHOU, China and ROCKVILLE, Md., March 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest results from three preclinical s...

2023-03-15 07:59 2940

Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011

SHANGHAI, March 14, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, launched first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW3011. The study (CTR20230046) is a phase 1, single cente...

2023-03-14 23:42 2251

Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma

NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an innovative oncology pharmaceutical company of Simcere has entered into a clinical collaboration agreeme...

2023-03-14 20:00 2522

Patient Enrollment Completed for Phase III Clinical Trial of Akeso's Cadonilimab in Treatment of Gastric Cancer

HONG KONG, March 14, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that patient enrollment has been completed for its pivotal Phase III clinical trial for cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104), the world's first approved and marketed dual-immune checkpoint bi-specific antib...

2023-03-14 17:01 1429

Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Development for Solid Tumors

SUZHOU, China, March 13, 2023 /PRNewswire/ -- On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. (Porton Advanced) and Bennu Biotherapeutics (Bennubio) announced a strategic partnership to advance cell and gene therapy R&D pipelines. The partnership aims to accelerate the development of T-...

2023-03-13 20:00 1715

Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing

BOSTON, March 9, 2023 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a biotech company focusing on next-generation precision medicine for oncology and autoimmune diseases, announces the completion of a$50 million Series B financing round, co-led by INCE Capital and Qiming Venture Partners, w...

2023-03-10 09:00 2005

GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting

SHANGHAI, March 9, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH312 (RIPK1 inhibitor) monotherapy will be presented as a poster at the 2023 ASC...

2023-03-09 19:00 1600

BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events

CAMBRIDGE, Mass. and DAEJEON, South Korea, March 8, 2023 /PRNewswire/ -- BIORCHESTRA , a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging its proprietary Brain-Targeting RNAi Nanomedi...

2023-03-08 22:47 1856

Hovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise

LISBON, Portugal, March 8, 2023 /PRNewswire/ -- Hovione, the leader in spray drying and particle engineering, won the2023 CDMO Leadership Award across all six categories – capability, compatibility, expertise, quality, reliability and service across all thre...

2023-03-08 22:00 1997

MSCI ESG Updated I-Mab to "A" Rating

GAITHERSBURG, MD. and SHANGHAI, March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (Morgan ...

2023-03-07 21:02 1822

AnPac Bio Announces Receipt of the First Payment from a Malaysia Customer On a Signed US$1.5 Million Cancer Detection Equipment Purchase Contract

NEW YORK, March 7, 2023 /PRNewswire/ – AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company" (Nasdaq: ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commer...

2023-03-07 20:30 1559

AnPac Bio-Medical Science Announces US$5 Million Private Placement

NEW YORK, March 6, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) ("AnPac Bio," the "Company" or "we"), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business ...

2023-03-06 21:30 3381

HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis

* The trial met its primary endpoint and key secondary endpoints, with a favorable safety profile * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China for the treatment of myasthenia gravis SEOUL, South Korea, March 6, 2023 /PRNewswire/ -- HanAll Biopharma...

2023-03-06 20:00 1633

Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy

SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd. (Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on February 27, 2023, a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics.

2023-03-02 20:00 2124

Sanyou Biopharmaceuticals opens Cambridge MA, US office, expanding its business outreach to a central hub of biotech network

CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech sta...

2023-03-02 18:00 1700

ExoCoBio obtained 2 GMP Licenses for Exosome Biopharmaceuticals from Korea MFDS and for Hyaluronic Acid (HA) Dermal Fillers from Brazil ANVISA

* ExoGMP™ is the world's largest exosome manufacturing facility in Osong, South Korea. * Cellosome™ HA fillers are expected to be approved in 2023. * ExoCoBio has all 3 types of GMP clearance for pharmaceuticals, medical devices, & cosmetics. SEOUL, South Korea, March 2, 2023 /PRNewswire/ -...

2023-03-02 14:09 3877

GenFleet receives EMA approval for phase Ib/II study of GFH925 (KRAS G12C inhibitor) in combination with ERBITUX® (cetuximab) treating patients with advanced NSCLC in first-line setting

SHANGHAI, March 1, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced today that European Medicine Agency (EMA) approved the phase Ib/II study of GFH925 (KRASG12C inhibitor) in combination wit...

2023-03-01 19:00 1933

First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary fibrosis has been approved by the Therapeutic Goods Admi...

2023-02-28 23:00 1807

Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference

SAN DIEGO Calif., and SUZHOU and SHANGHAI, China, Feb. 28, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of...

2023-02-28 21:00 1886

GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology

* Entered into an acquisition deal of 3 programs YONGIN, South Korea, Feb. 27, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : ...

2023-02-28 08:53 2217
1 ... 55565758596061 ... 127